One of the most compelling new clinical trials launched by City of Hope involves a nonsurgical treatment strategy for rectal cancer. This Phase 2 study investigates the efficacy of combining the FOLFOX chemotherapy regimen—consisting of fluorouracil, oxaliplatin, and leucovorin calcium—with immunotherapeutic agents botensilimab and balstilimab. Significantly, this combination is administered to patients with localized rectal adenocarcinoma who have not undergone surgery, aiming to evaluate whether this regimen can achieve tumor eradication without the need for conventional radiation or invasive surgery, which often result in long-term urinary and bowel dysfunction. This trial embodies a paradigm shift toward organ preservation and improved quality of life for patients confronting rectal cancer.

In parallel, City of Hope has initiated a Phase 1 trial exploring the use of triapine, an oral ribonucleotide reductase inhibitor, in conjunction with radiation therapy for patients with recurrent glioblastoma and astrocytoma. These malignancies represent some of the most intractable brain tumors, notorious for treatment resistance and poor prognosis. By inhibiting the enzyme critical for DNA synthesis, triapine disrupts tumor cell replication and potentially enhances radiosensitivity. The primary objective is dose-escalation to establish safety and tolerability, but investigators are also monitoring tumor response and symptom alleviation. Success in this trial could open new therapeutic avenues for a cancer type with limited options.

Advancing the frontier of diagnostic oncology, City of Hope researchers have developed a promising liquid biopsy for early gastric cancer detection. The innovation leverages exosome-derived microRNAs (miRNAs) as sensitive biomarkers retrievable from blood samples. Collaborating with institutions in high-incidence regions such as Japan and South Korea, the team applied machine learning algorithms to identify a signature panel of 10 miRNAs capable of detecting early-stage gastric cancer with 95% accuracy. This noninvasive approach, branded as DESTINEX, could revolutionize screening protocols, circumventing the limitations of current endoscopy-based methods by offering a less invasive, more accessible, and cost-effective option—particularly pertinent for populations where widespread endoscopic screening is impractical.

Immunological restoration post-cancer treatment is another critical domain illuminated by City of Hope’s research. Investigators have spotlighted a subset of hematopoietic stem cells characterized by low expression of the Kit receptor (Kit^lo HSC), which plays a pivotal role in rejuvenating thymic function and thereby enhancing T cell reconstitution after allogeneic hematopoietic cell transplantation—a common therapeutic procedure for hematological malignancies. Experimental murine models revealed that Kit^lo HSCs promote thymic recovery and boost adaptive immunity, even counteracting age-associated thymic decline, through complex genomic regulatory networks involving key transcription factors such as ZBTB1. These findings suggest that targeting or augmenting Kit^lo HSC populations could be transformative in improving immune resilience following cytotoxic therapies.

The intersection of social determinants and cancer epidemiology also emerges as a critical area of inquiry. A large-scale epidemiological analysis by City of Hope highlights how residential segregation correlates with an increased lung cancer incidence among Black Americans. Using data from over 71,000 individuals, the study identified that living in racially less segregated neighborhoods corresponded with a lower lung cancer risk. Factors such as menthol cigarette usage—a product disproportionately marketed to Black communities—and environmental air pollution were implicated as mediators. This research not only underscores the significance of structural racism in health disparities but also informs targeted public health interventions and policy reforms aimed at mitigating these inequities.

Beyond clinical and societal investigations, City of Hope is celebrating landmark recognition in diabetes research with faculty members receiving prestigious awards for their contributions to understanding metabolic diseases. These honors reflect the institution’s broad commitment to exploring the molecular underpinnings of diabetes and its intersections with cancer biology, thereby fostering interdisciplinary innovation.

The institution’s research ecosystem continues to thrive under substantial funding awards from federal agencies. Noteworthy grants include a $6.2 million NIH/NCI award supporting advances in natural killer cell biology, a $4.1 million project probing cellular stress pathways affecting pancreatic beta cells, and multimillion-dollar funds allocated to study immune cell development and epigenetic regulation within metabolic contexts. These investments underpin ongoing efforts to elucidate fundamental cellular mechanisms with translational potential.

Taken together, City of Hope’s multifaceted research portfolio demonstrates the power of integrating clinical trial innovation, biomarker discovery, immunology, epidemiology, and basic science. The institution’s work not only seeks to improve individual patient outcomes but also addresses broader public health challenges, aiming to make hope a tangible reality across diverse populations afflicted by cancer, diabetes, and other chronic diseases.

Subject of Research: Cancer treatment innovation, liquid biopsy diagnostics, immune system recovery, social determinants of lung cancer risk, diabetes and metabolism research.

Article Title: City of Hope Advances Cancer Care with Novel Clinical Trials, Diagnostic Innovations, and Insights into Immune Recovery and Health Disparities

News Publication Date: Not specified

Web References:

• Rectal Cancer Trial: https://clinicaltrials.gov/study/NCT06780787
• Glioblastoma Trial: https://clinicaltrials.gov/study/NCT06860594
• Gastric Cancer Biomarker Study: https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074
• Immune Recovery Research: https://www.nature.com/articles/s41467-025-61125-1
• Lung Cancer and Segregation Study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835843

References:

• Selection of peer-reviewed journal articles linked above.

Image Credits: City of Hope

The ATOMIC trial was meticulously designed as a phase 3 multicenter, randomized, open-label clinical investigation involving 712 patients diagnosed with surgically resected stage 3 colon tumors displaying dMMR. This molecular characteristic, also referred to as microsatellite instability-high (MSI-H), is indicative of an impaired DNA mismatch repair system, a hallmark that not only drives tumorigenesis but also sensitizes tumors to immunologic interventions. The trial sought to evaluate whether the integration of atezolizumab, an anti-PD-L1 monoclonal antibody immune checkpoint inhibitor, with the established FOLFOX chemotherapy protocol could substantially reduce the rate of cancer recurrence and improve overall outcomes.

In clinical oncology, adjuvant chemotherapy with FOLFOX—comprising 5-fluorouracil, leucovorin, and oxaliplatin—has been the standard of care following surgical resection of stage 3 colon cancer for decades. However, despite its widespread use, recurrence rates in patients with dMMR tumors remain a significant clinical challenge. Previous studies underscored the efficacy of immune checkpoint blockade in metastatic settings, but its potential benefits in the adjuvant, post-surgical context had not yet been elucidated with robust clinical evidence until now. The ATOMIC trial’s findings thus fill a crucial knowledge gap.

From September 2017 through January 2023, the trial enrolled a diverse cohort with a median age of 64, slightly more than half of whom were female. The randomized design allocated participants into two groups: one receiving standard FOLFOX chemotherapy alone and the other receiving FOLFOX combined with atezolizumab. The study’s primary endpoint centered on disease-free survival (DFS), a critical measure representing the duration patients remain free from any signs of cancer recurrence following treatment. Secondary endpoints scrutinized overall survival and adverse event profiles to assess long-term efficacy and safety.

The results reported are nothing short of remarkable. Patients treated with the combination therapy demonstrated a three-year DFS rate of 86.4%, a statistically significant increase compared to the 76.6% rate observed in those treated with chemotherapy alone. This 50% reduction in the risk of recurrence or death underscores the potent synergy between chemotherapy and immune checkpoint blockade, especially within the immunogenically active dMMR tumor microenvironment. The study authors highlight that this improvement is a potential game changer for the clinical management of a patient population previously limited to conventional cytotoxic regimens.

At the molecular level, dMMR tumors harbor defects in DNA repair enzymes responsible for correcting replication errors, leading to microsatellite instability — repetitive DNA sequences prone to insertion or deletion mutations. This high mutational burden increases neoantigen presentation, thereby enhancing tumor immunogenicity. Immune checkpoint inhibitors like atezolizumab work by blocking PD-L1, a ligand that tumors exploit to evade immune detection, effectively restoring cytotoxic T-cell activity against cancer cells. Combining this immune activation with cytotoxic chemotherapy likely potentiates tumor eradication via complementary mechanisms.

A notable aspect of the ATOMIC trial lies in its rigorous collaboration model. Sponsored primarily by the National Cancer Institute and coordinated through the Alliance for Clinical Trials in Oncology, the study was a testament to the power of multi-institutional cooperation under the National Clinical Trials Network (NCTN). Furthermore, partnerships with biotechnology leader Genentech and the German AIO group broadened the trial’s reach and resource base, fostering a comprehensive, international approach to colon cancer research.

Colorectal cancer remains among the top causes of cancer-related mortality worldwide, with an increasing incidence noted in younger adults under 50 years old over the past two decades. This trend is attributed in part to late-stage diagnoses and aggressive tumor biology in this demographic. The ATOMIC trial’s implications could not be timelier, offering a novel treatment paradigm that may improve survival outcomes and herald a shift toward precision oncology in the adjuvant setting.

Importantly, the trial also reported on the safety profile of combining atezolizumab with FOLFOX chemotherapy. While immune checkpoint inhibitors are known to carry risks of immune-related adverse events—ranging from mild rash to severe pneumonitis or colitis—the integration with chemotherapy remained tolerable, with side effects manageable within current clinical standards. This balance of efficacy and safety lends credibility to adopting this combination in routine clinical practice following further validation.

Dr. Jeffrey Meyerhardt, the senior author and co-chair of the Alliance Gastrointestinal Committee, emphasized the transformative potential of these findings. He described the results as “extremely compelling”, suggesting not only a new standard of care for this molecular subtype but also demonstrating the indispensable role of federally funded clinical research in accelerating discovery and improving patient lives. The success of the ATOMIC trial embodies how precision medicine and immuno-oncology are increasingly converging to advance cancer therapeutics.

As the oncology community digests these findings, the ATOMIC trial sets the stage for further exploration into adjuvant immunotherapy across other tumor profiles and stages. Ongoing studies are anticipated to dissect biomarkers of response and resistance, optimize combination schedules, and identify which patients derive maximal benefit from immune checkpoint blockade. The integration of atezolizumab in post-operative colon cancer treatment heralds a broader shift in oncologic management—one that capitalizes on tumor immunobiology and molecular stratification.

In summary, the ATOMIC study offers compelling evidence that the immune checkpoint inhibitor atezolizumab, when added to the standard chemotherapy backbone of FOLFOX, dramatically improves disease-free survival in patients with stage 3 colon cancer characterized by deficient mismatch repair. These findings underscore the promise of precision medicine approaches that leverage tumor genetics and immune modulation to enhance therapeutic efficacy. As this treatment paradigm gains traction, it stands to significantly alter the clinical landscape for a vulnerable subset of colon cancer patients and exemplifies the future of cancer care in the era of immunotherapy.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits: Dana-Farber Cancer Institute
Keywords: Colon cancer, Clinical trials, Cancer immunotherapy